Alembic Pharmaceuticals gets FDA approval for Dasatinib Tablets

TAGS

Alembic Pharmaceuticals has secured tentative approval for the abbreviated new drug application (ANDA) of Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg from the (FDA).

The tentatively approved product is the generic of Bristol Myers Squibb Company’s Sprycel Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg.

See also  Bristol Myers Squibb to acquire MyoKardia for $13.1bn: A strategic move to strengthen cardiovascular portfolio

Dasatinib Tablet is indicated for newly diagnosed Philadelphia chromosome-positive (Ph+) (CML) in chronic phase, chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and Philadelphia chromosome-positive acute lymphoblastic (Ph+ ALL) with resistance or intolerance to prior therapy. It is approved for use in adult patients only.

See also  Varicose Veins symptoms and home remedies

According to IQVIA, Dasatinib Tablets have an estimated market size of $1.46bn for 12 months ending December 2021.

Alembic Pharmaceuticals gets FDA approval for Dasatinib Tablets

gets FDA approval for Dasatinib Tablets. Photo courtesy of Bluerasberry/Wikipedia.org.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This